SYDNEY: EVE Health Group (ASX: EVE) announced Monday it has agreed to acquire Australian biotech firm Nextract Pty Ltd, marking its entry into the $5.3 billion global erectile dysfunction market. The deal, valued at $3 million in equity, is part of EVE’s shift from natural wellness products into regulated pharmaceutical and nutraceutical markets. Nextract’s lead…